Laurus Labs Q2 profit more than doubles on 33% revenue growth

Laurus Labs reported a more than twofold jump in consolidated net profit to ₹436.74 crore for the September quarter, as revenue from operations rose 33% to ₹2,206.37 crore. The pharma company has started its first commercial-scale peptide plant in Visakhapatnam and is acquiring a 60% stake in Montreal-based research firm Galenvs Sciences.